X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ALKEM LABORATORIES - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ALKEM LABORATORIES CIPLA/
ALKEM LABORATORIES
 
P/E (TTM) x 33.4 - - View Chart
P/BV x 2.9 6.5 45.0% View Chart
Dividend Yield % 0.6 0.7 86.9%  

Financials

 CIPLA   ALKEM LABORATORIES
EQUITY SHARE DATA
    CIPLA
Mar-18
ALKEM LABORATORIES
Mar-16
CIPLA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6631,589 41.7%   
Low Rs4791,232 38.9%   
Sales per share (Unadj.) Rs189.0417.5 45.3%  
Earnings per share (Unadj.) Rs17.656.3 31.3%  
Cash flow per share (Unadj.) Rs34.064.7 52.6%  
Dividends per share (Unadj.) Rs3.0012.70 23.6%  
Dividend yield (eoy) %0.50.9 58.4%  
Book value per share (Unadj.) Rs176.7292.9 60.3%  
Shares outstanding (eoy) m805.12119.57 673.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.4 89.4%   
Avg P/E ratio x32.525.1 129.5%  
P/CF ratio (eoy) x16.821.8 77.0%  
Price / Book Value ratio x3.24.8 67.1%  
Dividend payout %17.122.6 75.6%   
Avg Mkt Cap Rs m459,724168,653 272.6%   
No. of employees `00023.6NA-   
Total wages/salary Rs m26,9019,171 293.3%   
Avg. sales/employee Rs Th6,446.1NM-  
Avg. wages/employee Rs Th1,139.4NM-  
Avg. net profit/employee Rs Th600.0NM-  
INCOME DATA
Net Sales Rs m152,19349,915 304.9%  
Other income Rs m3,5771,645 217.4%   
Total revenues Rs m155,76951,561 302.1%   
Gross profit Rs m28,2648,482 333.2%  
Depreciation Rs m13,2281,006 1,315.2%   
Interest Rs m1,142671 170.3%   
Profit before tax Rs m17,4708,451 206.7%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,5011,606 155.7%   
Profit after tax Rs m14,1666,731 210.4%  
Gross profit margin %18.617.0 109.3%  
Effective tax rate %14.319.0 75.3%   
Net profit margin %9.313.5 69.0%  
BALANCE SHEET DATA
Current assets Rs m108,14127,062 399.6%   
Current liabilities Rs m38,32215,324 250.1%   
Net working cap to sales %45.923.5 195.1%  
Current ratio x2.81.8 159.8%  
Inventory Days Days9767 145.9%  
Debtors Days Days7441 180.2%  
Net fixed assets Rs m109,41112,610 867.7%   
Share capital Rs m1,610239 673.4%   
"Free" reserves Rs m140,68234,490 407.9%   
Net worth Rs m142,29235,027 406.2%   
Long term debt Rs m36,6211,212 3,022.5%   
Total assets Rs m228,60654,387 420.3%  
Interest coverage x16.313.6 119.8%   
Debt to equity ratio x0.30 744.0%  
Sales to assets ratio x0.70.9 72.5%   
Return on assets %6.713.6 49.2%  
Return on equity %10.019.2 51.8%  
Return on capital %10.024.9 40.0%  
Exports to sales %32.812.9 253.2%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs m49,8836,461 772.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m51,6916,563 787.6%   
Fx outflow Rs m21,0333,012 698.4%   
Net fx Rs m30,6583,552 863.2%   
CASH FLOW
From Operations Rs m14,6287,259 201.5%  
From Investments Rs m-8,5401,864 -458.1%  
From Financial Activity Rs m-3,855-9,273 41.6%  
Net Cashflow Rs m2,431-150 -1,620.7%  

Share Holding

Indian Promoters % 16.0 66.9 23.9%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 33.1 36.9%  
FIIs % 23.7 0.0 -  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 0.0 -  
Shareholders   161,166 68,381 235.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PFIZER  ABBOTT INDIA  FRESENIUS KABI ONCO.  DR. REDDYS LAB  GSK PHARMA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Prepare to Ride Out Volatile Markets with Rahul Shah(Podcast)

Watching the stock market basically volatile on a regular basis isn't easy. Catch Rahul Shah talk about his mantra to ride out the volatility in times like these.

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Why Qualitative Aspects Are So Important To Pick Mutual Funds(Outside View)

Nov 26, 2018

PersonalFN briefly outlines why qualitative parameters are equally important in selecting mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Dec 7, 2018 (Close)

TRACK CIPLA

CIPLA - ALEMBIC LTD COMPARISON

COMPARE CIPLA WITH

MARKET STATS